Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Category list : Antineoplastic agents

Sort by: Newest first Oldest first A-Z Z-A

  • Mark Drakeford (pictured), health minister for Wales, says there will not be a Cancer Drugs Fund for Wales

    Wales will not have a Cancer Drugs Fund, health minister says Subscription

    12 NOV 2014 17:46 By Graeme Smith

    Wales will not have a Cancer Drugs Fund, despite a 98,000-signature petition calling for equity of access to cancer drugs for patients in England and Wales being handed to the Welsh Assembly on 5 November 2014.

  • Vemurafenib shows potential as targeted melanoma therapy

    28 JUN 2011 11:36

    Genetically-targeted chemotherapy combinations based on the BRAF-kinase inhibitor vemurafenib are going on trial for the treatment of metastatic malignant melanoma.

  • Vemurafenib pack shot

    Vemurafenib resistance pathway yields targets for melanoma treatment

    30 MAY 2014 14:20

    Researchers from Cancer Research UK have identified a family of proteins that mediate the development of resistance to vemurafenib, a BRAF enzyme inhibitor used to treat patients with advanced melanoma.

  • The efficacy and safety of amphotericin plus miltefosine to treat visceral leishmaniasis (VL) patients with HIV will be examined in a Phase III randomized clinical trial in Ethiopia.

    Treatment tested for patients with visceral leishmaniasis and HIV in Africa Subscription

    21 OCT 2014 14:07

    The efficacy and safety of amphotericin plus miltefosine to treat visceral leishmaniasis patients with HIV will be examined in a Phase III randomized clinical trial in Ethiopia.

  • Intravenous chemotherapy (Tawesit/Dreamstime.com)

    Teva launches new pegylated filgrastim for reduction of neutropenia

    27 FEB 2014 14:13

    Teva has launched a new pegylated form of filgrastim. It is licensed for reduction of duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy.

  • Temozolomide for melanoma

    22 JAN 2000 0:00

    Temozolomide (Temodal) is as effective as dacarbazine for metastatic melanoma and has the advantage of being an oral preparation, say Dr Mark Middleton (department of medical oncology, Christie hospital NHS trust, Manchester) and colleagues.

  • Tafinlar capsules (dabrafenib; GlaxoSmithKline)

    Targeted oral anti-melanoma therapy dabrafenib set for UK launch

    2 JAN 2014 15:34

    Healthcare professionals will soon be able to add dabrafenib — a targeted oral anti-cancer therapy — to the armoury of medicines available to treat patients with melanoma.

  • Targeted cancer therapy Subscription

    1 FEB 2013

    Reflection and evaluation are elements of the CPD cycle that pharmacists often find difficult, yet they are integral to producing valid, and rewarding, CPD records.

  • Target high-risk people for melanoma screening

    2 JUN 2010 10:11

    Targeting high-risk individuals for screening could be the best way to improve early detection and treatment of malignant melanoma Alexander Stratigos, of the department of dermatology at the University of Athens Medical School, told the audience during a session at the European Association of Dermatology and Venereology 2010 Spring Symposium.

  • Scientific advances are not translating into new cancer drugs, expert warns Subscription

    27 OCT 2014 14:51

    The global system for discovering new cancer drugs is failing to turn scientific advances into innovative new medicines, Paul Workman, interim chief executive of The Institute of Cancer Research in London has warned.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.